Understanding the Oncology Care Model

The Centers for Medicare & Medicaid Services introduced the Oncology Care Model systemic therapy payment structure to improve value. This model uses an episode-based system. Systemic therapy starts trigger these payments. Consequently, many experts worried that this financial incentive might unintentionally prompt practices to increase the volume of treatments. However, recent findings suggest these fears are unfounded.

Study Design and Methodology

Researchers analyzed data from over 750,000 Medicare beneficiaries treated between 2010 and 2019. They utilized a matched difference-in-differences analysis to compare OCM practices with non-participating practices. Specifically, the team examined two groups: those with newly diagnosed incident cancers and those with poor-prognosis cancers. Furthermore, this approach allowed investigators to see if the incentive of monthly care payments led to more frequent therapy initiation.

Impact on the Oncology Care Model Systemic Therapy Initiation

The findings indicate that the OCM did not lead to an increase in treatment initiation for the incident cancer population. Specifically, there was no statistically significant change in the likelihood of starting systemic therapy. Furthermore, among patients with poor-prognosis cancers, the model was actually associated with a 1.5 percentage point decrease in therapy initiation. This suggests that the model may have encouraged more selective, value-based treatment decisions rather than simply driving volume.

Financial Savings and Clinical Implications

Beyond treatment frequency, the study measured total Medicare payments. In the year following a diagnosis, spending for poor-prognosis patients dropped by approximately $2,192 per patient in OCM practices. While savings in the incident diagnosis group were not statistically significant, the overall trend suggests efficiency improvements. Consequently, the OCM evaluation reveals hidden savings. These savings come from avoiding unnecessary chemotherapy in advanced stages.

FAQs

Did the Oncology Care Model lead to more patients starting chemotherapy?

No, the study found no evidence that the model increased the initiation of systemic therapy for patients with incident cancers. Instead, it showed a decrease in treatment initiation among those with poor-prognosis cancers.

How did the OCM impact healthcare spending?

The study found a significant decrease in spending among patients with poor-prognosis cancers. Specifically, it saved over $2,000 per patient annually. This suggests the model successfully targeted high-cost care in advanced cancer stages.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

Keating NL et al. The Oncology Care Model and Initiation of Systemic Therapy for Cancer. JAMA Intern Med. 2026 Apr 27. doi: 10.1001/jamainternmed.2026.1085. PMID: 42043828.

Brooks GA et al. The Oncology Care Model and Medicare Payments, Utilization, and Quality. JAMA. 2026 Mar 25. doi: 10.1001/jama.2026.2075. PMID: 41879763.

CMS Innovation Center. Evaluation of the Oncology Care Model: Final Report. 2022. Available at: https://innovation.cms.gov/initiatives/oncology-care/